A Study of Mirikizumab in Participants With Plaque Psoriasis

• Status: Completed
• Trial end date: 2019-10-28
• Target enrollment: 0
• Participant gender: All

Summary

This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab.

The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Mirikizumab

Criteria

Inclusion Criteria:

• Males and females with chronic plaque psoriasis for at least 6 months who are candidates for systemic therapy or phototherapy

• Have greater than or equal to (≥) 10 percent body surface area (BSA) involvement at screening and first admission to the clinical site

Exclusion Criteria:

• Pregnant or nursing (lactating)

• History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis infection

• Have major surgery within 8 weeks prior to first admission to the clinical site or during the study

• Have a history of lymphoma, leukemia, or any malignancy

• Require treatment with the cocktail drugs within 14 days prior to the first administration of the drug cocktail through the end of Week 12 assessments

• Have participated in any other study with mirikizumab